Collaborative Research Grant – Soft Tissue Sarcoma
The External Collaborative Research (ECR) program is open to all qualified academic and community-based scientists or consortia that are interested in proposing a study and wish to collaborate with Boehringer Ingelheim to develop a protocol and analyze and publish the results.
In addition to providing intellectual contributions, Boehringer Ingelheim may provide drug and/or financial support for an ECR. Boehringer Ingelheim does not serve as the regulatory sponsor for an ECR.
-
Real-world data: The natural history, development and progression of the disease, molecular testing and pathological subtyping, diagnostic/treatment landscape, and efficacy/safety outcomes
-
Monotherapy or combination therapy (including novel treatment combinations or radiotherapy) in MDM2 amplified or overexpressed tumors (p53 wild type)
The preliminary budget for ECRs should reflect fair market value for all costs and cannot include direct
salary support for the principal investigator. Budgets for ECRs will be further negotiated pending
finalization of the collaborative protocol.
Although the research interests listed within the therapeutic areas are of focus to Boehringer Ingelheim,
other research interests may be considered.
Proposals in the following areas are not being considered:
Biosimilars and Fibrosing ILDs
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.